

# Philip S Wells

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6538586/philip-s-wells-publications-by-citations.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

189  
papers

17,658  
citations

37  
h-index

132  
g-index

195  
ext. papers

21,038  
ext. citations

8.4  
avg, IF

6.2  
L-index

#	Paper	IF	Citations
189	Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. <i>Chest</i> , <b>2016</b> , 149, 315-352	5.3	3090
188	Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, e419S-e496S	5.3	2575
187	Oral rivaroxaban for symptomatic venous thromboembolism. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 2499-510	59.2	2240
186	Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1287-97	59.2	1692
185	Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 1227-35	59.2	1018
184	A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. <i>New England Journal of Medicine</i> , <b>1999</b> , 340, 901-7	59.2	876
183	Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 631-9	59.2	609
182	Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, e351S-e418S	5.3	449
181	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1211-1222	59.2	397
180	Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 711-719	59.2	391
179	Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report. <i>Chest</i> , <b>2020</b> , 158, 1143-1163	5.3	356
178	Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. <i>Lancet, The</i> , <b>2014</b> , 383, 880-8	40	322
177	Does this patient have deep vein thrombosis?. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 199-207	27.4	256
176	Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 699-707	59.2	189
175	Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. <i>Lancet Haematology, the</i> , <b>2014</b> , 1, e37-46	14.6	186
174	Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. <i>Lancet, The</i> , <b>2014</b> , 384, 1673-83	40	168
173	A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis. <i>Circulation</i> , <b>1995</b> , 91, 2184-7	16.7	152

172	Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. <i>Circulation</i> , <b>2012</b> , 126, 448-54	16.7	142
171	Treatment of venous thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 717-28	27.4	133
170	Venous Thromboembolism: Advances in Diagnosis and Treatment. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 320, 1583-1594	27.4	128
169	A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. <i>Archives of Internal Medicine</i> , <b>2005</b> , 165, 733-8		124
168	Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. <i>Blood</i> , <b>2016</b> , 127, 1417-25	2.2	122
167	Functional and Exercise Limitations After a First Episode of Pulmonary Embolism: Results of the ELOPE Prospective Cohort Study. <i>Chest</i> , <b>2017</b> , 151, 1058-1068	5.3	111
166	Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin. <i>Thrombosis and Haemostasis</i> , <b>1994</b> , 71, 300-304	7	106
165	Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-analysis. <i>Thrombosis Research</i> , <b>2013</b> , 132, 515-9	8.2	100
164	The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. <i>Archives of Internal Medicine</i> , <b>2003</b> , 163, 917-20		93
163	Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 1122-35	27.4	92
162	Long-range epigenetic regulation is conferred by genetic variation located at thousands of independent loci. <i>Nature Communications</i> , <b>2015</b> , 6, 6326	17.4	90
161	Quality of Life, Dyspnea, and Functional Exercise Capacity Following a First Episode of Pulmonary Embolism: Results of the ELOPE Cohort Study. <i>American Journal of Medicine</i> , <b>2017</b> , 130, 990.e9-990.e21	2.4	73
160	Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis. <i>American Journal of Epidemiology</i> , <b>2006</b> , 164, 101-9	3.8	70
159	Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding: Characteristics, Reversal Strategies, and Outcomes From a Multicenter Observational Study. <i>Chest</i> , <b>2017</b> , 152, 81-91	5.3	53
158	Application of a Novel and Rapid Whole Blood Assay for D-Dimer in Patients with Clinically Suspected Pulmonary Embolism. <i>Thrombosis and Haemostasis</i> , <b>1995</b> , 73, 035-038	7	53
157	Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. <i>Chest</i> , <b>2021</b> , 160, e545-e608	5.3	48
156	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. <i>Blood Advances</i> , <b>2018</b> , 2, 788-796	7.8	46
155	Factors that predict thrombosis in relatives of patients with venous thromboembolism. <i>Blood</i> , <b>2014</b> , 124, 2124-30	2.2	43

154	The diagnosis and treatment of venous thromboembolism. <i>Hematology American Society of Hematology Education Program</i> , <b>2013</b> , 2013, 457-63	3.1	43
153	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , <b>2016</b> , 3, e228-36	14.6	41
152	Safety and efficacy of methods for reducing perioperative allogeneic transfusion: a critical review of the literature. <i>American Journal of Therapeutics</i> , <b>2002</b> , 9, 377-88	1	37
151	Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. <i>Chest</i> , <b>2021</b> , 160, 2247-2259	5.3	35
150	Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism. <i>American Journal of Medicine</i> , <b>2017</b> , 130, 588-595	2.4	34
149	Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer patients at intermediate-high risk for venous thrombosis. <i>Thrombosis Research</i> , <b>2015</b> , 136, 1099-102	8.2	34
148	Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 2141-2151	15.4	31
147	Advances in the diagnosis of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2006</b> , 21, 31-40	5.1	29
146	Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study. <i>Thrombosis Research</i> , <b>2018</b> , 163, 41-46	8.2	27
145	Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study. <i>Academic Emergency Medicine</i> , <b>2015</b> , 22, 299-307	3.4	26
144	Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: A multi-national cohort. <i>Thrombosis Research</i> , <b>2016</b> , 143, 152-8	8.2	25
143	Diagnosis of Venous Thromboembolism: 20 Years of Progress. <i>Annals of Internal Medicine</i> , <b>2018</b> , 168, 131-140	8	24
142	Endovascular cooling catheter related thrombosis in patients undergoing therapeutic hypothermia for out of hospital cardiac arrest. <i>Resuscitation</i> , <b>2014</b> , 85, 1354-8	4	23
141	Surgical treatment of chronic thromboembolic pulmonary hypertension. <i>Canadian Respiratory Journal</i> , <b>2000</b> , 7, 49-57	2.1	23
140	Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , <b>2016</b> , 3, e437-45	14.6	23
139	Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial. <i>Thrombosis Research</i> , <b>2018</b> , 164 Suppl 1, S124-S129	8.2	21
138	Clinical decision rules and D-Dimer in venous thromboembolism: current controversies and future research priorities. <i>Thrombosis Research</i> , <b>2014</b> , 134, 763-8	8.2	21
137	Blood triglyceride levels are associated with DNA methylation at the serine metabolism gene PHGDH. <i>Scientific Reports</i> , <b>2017</b> , 7, 11207	4.9	20

136	Bleeding risk in patients with unprovoked venous thromboembolism: A critical appraisal of clinical prediction scores. <i>Thrombosis Research</i> , <b>2017</b> , 152, 52-60	8.2	19
135	Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension. <i>Chest</i> , <b>2016</b> , 150, 1059-1068	5.3	19
134	Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. <i>Thrombosis Research</i> , <b>2018</b> , 162, 7-14	8.2	18
133	Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding. <i>Academic Emergency Medicine</i> , <b>2016</b> , 23, 144-50	3.4	18
132	Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study. <i>Thrombosis Research</i> , <b>2018</b> , 162, 104-109	8.2	17
131	Timing of vitamin K antagonist re-initiation following intracranial hemorrhage in mechanical heart valves: Systematic review and meta-analysis. <i>Thrombosis Research</i> , <b>2016</b> , 144, 152-7	8.2	16
130	Diagnosis of pulmonary embolism: when is imaging needed?. <i>Clinics in Chest Medicine</i> , <b>2003</b> , 24, 13-28	5.3	16
129	D-dimer for pulmonary embolism. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1668-9	27.4	15
128	The diagnosis of venous thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2012</b> , 38, 691-701	5.3	14
127	Alignment to ACCP Prophylaxis Guidelines and VTE Outcomes in THR and TKR Patients. <i>Blood</i> , <b>2008</b> , 112, 170-170	2.2	14
126	Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2017</b> , 23, 830-837	3.3	13
125	Pulmonary embolism: a clinician's perspective. <i>Seminars in Nuclear Medicine</i> , <b>2008</b> , 38, 404-11	5.4	13
124	Analysis of venous thromboprophylaxis duration and outcomes in orthopedic patients. <i>American Journal of Managed Care</i> , <b>2010</b> , 16, 857-63	2.1	13
123	Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy. <i>Thrombosis Journal</i> , <b>2014</b> , 12, 26	5.6	12
122	Rivaroxaban shows promise as effective therapy for cancer patients with venous thromboembolic disease. <i>Thrombosis Research</i> , <b>2017</b> , 152, 4-6	8.2	11
121	DNA methylation age is associated with an altered hemostatic profile in a multiethnic meta-analysis. <i>Blood</i> , <b>2018</b> , 132, 1842-1850	2.2	11
120	Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. <i>Internal and Emergency Medicine</i> , <b>2017</b> , 12, 311-318	3.7	11
119	Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants. <i>American Journal of Kidney Diseases</i> , <b>2020</b> , 76, 311-320	7.4	10

118	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. <i>Thrombosis Research</i> , <b>2018</b> , 168, 121-129	8.2	10
117	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. <i>Thrombosis Research</i> , <b>2017</b> , 149, 29-37	8.2	10
116	Practical application of the 10-mg warfarin initiation nomogram. <i>Blood Coagulation and Fibrinolysis</i> , <b>2009</b> , 20, 403-8	1	10
115	The role of qualitative D-dimer assays, clinical probability, and noninvasive imaging tests for the diagnosis of deep vein thrombosis and pulmonary embolism. <i>Seminars in Vascular Medicine</i> , <b>2005</b> , 5, 340-50		10
114	The value of sPESI for risk stratification in patients with pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 149-157	5.1	9
113	An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. <i>Journal of Medical Economics</i> , <b>2011</b> , 14, 238-44	2.4	9
112	Benefit of early discharge among patients with low-risk pulmonary embolism. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185022	5.0	9
111	Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. <i>BMJ, The</i> , <b>2021</b> , 373, n1205	5.9	9
110	Genetically defined elevated homocysteine levels do not result in widespread changes of DNA methylation in leukocytes. <i>PLoS ONE</i> , <b>2017</b> , 12, e0182472	3.7	8
109	Timing of anticoagulant re-initiation following intracerebral hemorrhage in mechanical heart valves: Survey of neurosurgeons and thrombosis experts. <i>Clinical Neurology and Neurosurgery</i> , <b>2017</b> , 154, 23-27	2	7
108	Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation : A Multicenter Prospective Cohort Study. <i>Annals of Internal Medicine</i> , <b>2021</b> ,	8	7
107	Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. <i>Haematologica</i> , <b>2020</b> , 105, 1436-1442	6.6	7
106	Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 1420-1429	8	7
105	Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE. <i>Clinical Therapeutics</i> , <b>2017</b> , 39, 1396-1408	3.5	6
104	Thromboprophylaxis in Patients with COVID-19. A Brief Update to the CHEST Guideline and Expert Panel Report.. <i>Chest</i> , <b>2022</b> ,	5.3	6
103	Management of direct oral anticoagulant associated bleeding: Results of a multinational survey. <i>Thrombosis Research</i> , <b>2018</b> , 163, 19-21	8.2	5
102	Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding. <i>Thrombosis Research</i> , <b>2019</b> , 182, 12-19	8.2	5
101	Safety of Primary Thromboprophylaxis Using Apixaban in Ambulatory Cancer Patients with Intracranial Metastatic Disease or Primary Brain Tumors. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 1886-1887	7.7	5

100	Feasibility of blinding in a randomized controlled trial comparing preoperative autologous blood donation and acute normovolemic hemodilution in adult cardiac surgery. <i>Transfusion</i> , <b>2000</b> , 40, 1058-62	2.9	5
99	"Post-Pulmonary Embolism Syndrome" after a First Episode of PE: Results of the E.L.O.P.E. Study. <i>Blood</i> , <b>2015</b> , 126, 650-650	2.2	5
98	D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer. <i>Oncologist</i> , <b>2020</b> , 25, 1075-1083	5.7	5
97	N-terminal of prohormone brain natriuretic peptide predicts functional limitation one year following pulmonary embolism: Results from the ELOPE study. <i>Thrombosis Research</i> , <b>2017</b> , 153, 47-49	8.2	4
96	Homocysteine levels associate with subtle changes in leukocyte DNA methylation: an epigenome-wide analysis. <i>Epigenomics</i> , <b>2017</b> , 9, 1403-1422	4.4	4
95	Computed Tomographic Pulmonary Angiography for Pulmonary Embolism. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 314, 74-5	27.4	4
94	Nonleg venous thrombosis in critically ill adults. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 411-2	27.4	4
93	Venous thromboembolism prevention in intracerebral hemorrhage: A systematic review and network meta-analysis. <i>PLoS ONE</i> , <b>2020</b> , 15, e0234957	3.7	4
92	Sex Differences in Patients With Occult Cancer After Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2018</b> , 24, 489-495	3.3	4
91	The factor XIII Val34Leu polymorphism: is it protective against idiopathic venous thromboembolism?. <i>Blood Coagulation and Fibrinolysis</i> , <b>2006</b> , 17, 533-8	1	4
90	Double Blind Randomized Control Trial of Postoperative Low Molecular Weight Heparin Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2). <i>Blood</i> , <b>2018</b> , 132, 424-424	2.2	4
89	A Meta-Analysis to Determine the Risk of Heparin Induced Thrombocytopenia (HIT) and Isolated Thrombocytopenia in Prophylaxis Studies Comparing Unfractionated Heparin (UFH) and Low Molecular Weight Heparin (LMWH).. <i>Blood</i> , <b>2004</b> , 104, 2587-2587	2.2	4
88	Rivaroxaban for Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia Study. <i>Blood</i> , <b>2015</b> , 126, 3468-3468	2.2	4
87	Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population. <i>Chest</i> , <b>2018</b> , 154, 1371-1378	5.3	4
86	Venous Thromboembolism Prophylaxis in Critically Ill Adults: A Systematic Review and Network Meta-analysis. <i>Chest</i> , <b>2021</b> ,	5.3	4
85	Overview and comparison of D-dimer assay kits for DVT and PE. <i>Clinical Advances in Hematology and Oncology</i> , <b>2004</b> , 2, 160, 178	0.6	4
84	External validation of a claims-based and clinical approach for predicting post-pulmonary embolism outcomes among United States veterans. <i>Internal and Emergency Medicine</i> , <b>2017</b> , 12, 613-619	3.7	3
83	Predictive analytics by deep machine learning: A call for next-gen tools to improve health care. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2020</b> , 4, 181-182	5.1	3

82	Outcomes associated with observation stays versus inpatient admissions for pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2016</b> , 42, 513-9	5.1	3
81	Safety and Efficiency of Diagnostic Strategies for Ruling Out Pulmonary Embolism in Clinically Relevant Patient Subgroups : A Systematic Review and Individual-Patient Data Meta-analysis.. <i>Annals of Internal Medicine</i> , <b>2021</b> ,	8	3
80	Inflammation Markers and The Risk Of Post Thrombotic Syndrome: Results From The Bio-Sox Study. <i>Blood</i> , <b>2013</b> , 122, 36-36	2.2	3
79	A Prospective Cohort Study of Upper Extremity Deep Vein Thrombosis. <i>Blood</i> , <b>2015</b> , 126, 893-893	2.2	3
78	Association of Splanchnic Vein Thrombosis on Survival: 15-Year Institutional Experience With 1561 Cases. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e016600	6	3
77	Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study. <i>Thrombosis Research</i> , <b>2020</b> , 191 Suppl 1, S31-S36	8.2	3
76	Long-term risk of recurrent venous thromboembolism after a first contraceptive-related event: Data from REVERSE cohort study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 1526-1532	15.4	3
75	Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. <i>International Journal of Clinical Practice</i> , <b>2017</b> , 71, e12915	2.9	2
74	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. <i>TH Open</i> , <b>2018</b> , 2, e1-e7	2.7	2
73	Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism. <i>Clinical Therapeutics</i> , <b>2017</b> , 39, 1426-1436.e2	3.5	2
72	Evaluation of Definitions for Oral Anticoagulant-Associated Major Bleeding: A Population-Based Cohort Study. <i>Blood</i> , <b>2018</b> , 132, 426-426	2.2	2
71	Computerized Tomographic Pulmonary Angiography Compared with Ventilation-Perfusion Lung Scanning as Initial Diagnostic Modality for Patients with Suspected Pulmonary Embolism: A Randomized Controlled Trial.. <i>Blood</i> , <b>2005</b> , 106, 1619-1619	2.2	2
70	Indirect Comparisons of Rivaroxaban Versus Alternative Prophylaxes for the Prevention of VTE in Patients Undergoing Total Knee Replacement.. <i>Blood</i> , <b>2008</b> , 112, 1292-1292	2.2	2
69	A Systematic Review and Meta-Analysis of Proportions of Thrombosis and Bleeding in Patients Receiving Venous Thromboembolism (VTE) Prophylaxis After Orthopedic Surgery (OS). An Update.. <i>Blood</i> , <b>2009</b> , 114, 3125-3125	2.2	2
68	Development of A Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism In Patients with Cancer-Associated Venous Thromboembolism. <i>Blood</i> , <b>2010</b> , 116, 475-475	2.2	2
67	Predictors Of The Post-Thrombotic Syndrome In a Large Cohort Of Patients With Proximal DVT: Secondary Analysis Of The Sox Trial. <i>Blood</i> , <b>2013</b> , 122, 460-460	2.2	2
66	Prediction of Bleeding Risk in Patients on Extended Oral Anticoagulation for Venous Thromboembolism. <i>Blood</i> , <b>2016</b> , 128, 139-139	2.2	2
65	Post-Thrombotic Syndrome and Functional Disability in Patients with Upper Extremity Deep Vein Thrombosis: A Prospective Cohort Study. <i>Blood</i> , <b>2016</b> , 128, 417-417	2.2	2



64	Efficacy and safety of primary thromboprophylaxis for the prevention of venous thromboembolism in patients with cancer and a central venous catheter: A systematic review and meta-analysis. <i>Thrombosis Research</i> , <b>2021</b> , 208, 58-65	8.2	2
63	Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism. <i>Journal of Health Economics and Outcomes Research</i> , <b>2019</b> , 6, 84-94	1.6	2
62	Applying rigorous eligibility criteria to studies evaluating prognostic utility of serum biomarkers in pulmonary embolism: A systematic review and meta-analysis. <i>Thrombosis Research</i> , <b>2020</b> , 195, 195-208	8.2	2
61	Regarding the necessity of an updated meta-analysis on the prognostic value of serum biomarkers in patients with pulmonary embolism. <i>Thrombosis Research</i> , <b>2019</b> , 176, 8-10	8.2	2
60	Safety of using direct oral anticoagulants in the diagnostic workup of outpatients with suspicion of acute venous thromboembolism. <i>Haematologica</i> , <b>2020</b> , 105, e307-e309	6.6	2
59	Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: a post-hoc analysis of the avert trial. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 51, 720-724	5.1	2
58	Safety and efficacy of apixaban thromboprophylaxis in cancer patients with metastatic disease: A post-hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , <b>2021</b> , 197, 13-15	8.2	2
57	Leveraging cell type specific regulatory regions to detect SNPs associated with tissue factor pathway inhibitor plasma levels. <i>Genetic Epidemiology</i> , <b>2017</b> , 41, 455-466	2.6	1
56	Risk Stratification of Pulmonary Embolism. <i>Critical Care Clinics</i> , <b>2020</b> , 36, 437-448	4.5	1
55	Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results. <i>Journal of Medical Economics</i> , <b>2018</b> , 21, 587-594	2.4	1
54	Observation management of pulmonary embolism and agreement with claims-based and clinical risk stratification criteria in United States patients: a retrospective analysis. <i>BMC Pulmonary Medicine</i> , <b>2017</b> , 17, 37	3.5	1
53	Ruling out pulmonary embolism across different healthcare settings: A systematic review and individual patient data meta-analysis.. <i>PLoS Medicine</i> , <b>2022</b> , 19, e1003905	11.6	1
52	Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial.. <i>Thrombosis Research</i> , <b>2022</b> , 211, 85-87	8.2	1
51	A Pilot Study of Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis of the Upper Extremity (UEDVT).. <i>Blood</i> , <b>2006</b> , 108, 878-878	2.2	1
50	Trousseau's Syndrome Revisited: Should We Screen Extensively for Malignancy in Patients with Venous Thromboembolism? a Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2008</b> , 112, 403-403	2.2	1
49	A Randomized, Controlled Two-Center Pilot Trial of a 6-Month Exercise Training Program to Treat the Post-Thrombotic Syndrome: The EXPO Pilot Trial.. <i>Blood</i> , <b>2009</b> , 114, 3984-3984	2.2	1
48	Dyspnea, Quality of Life and Walking Capacity during 1 Year Follow-up after a First Episode of Pulmonary Embolism: Results of the E.L.O.P.E. Study. <i>Blood</i> , <b>2015</b> , 126, 750-750	2.2	1
47	Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer.. <i>Cmaj</i> , <b>2021</b> , 193, E1551-E1560	3.5	1

46	Ximelagatran in Major Orthopedic Surgery: A Systematic Review and Meta-Analysis of Efficacy and Safety.. <i>Blood</i> , <b>2005</b> , 106, 913-913	2.2	1
45	Apixaban anti-Xa level monitoring in treatment of acute upper extremity deep vein thrombosis for patient on chronic hemodialysis: a case report. <i>Thrombosis Journal</i> , <b>2021</b> , 19, 23	5.6	1
44	Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , <b>2021</b> , 202, 151-154	8.2	1
43	A cross-sectional study of the interrelationship between burnout, empathy and resilience in academic physicians. <i>Psychology, Health and Medicine</i> , <b>2021</b> , 1-8	2.1	1
42	Outcomes associated with observation status versus inpatient management of pulmonary embolism patients anticoagulated with rivaroxaban. <i>International Journal of Cardiology</i> , <b>2016</b> , 222, 846-849	3.3	1
41	Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 2801-2813	15.4	1
40	Life dissatisfaction in Canadians aged 40 and above with cancer and mental health disorders: A cross-sectional study using the Canadian Community Health Survey. <i>Cancer Medicine</i> , <b>2021</b> , 10, 7601-7609	4.8	1
39	The impact of Stress Management and Resilience Training (SMART) on academic physicians during the implementation of a new Health Information System: An exploratory randomized controlled trial.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0267240	3.7	1
38	Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study. <i>Haematologica</i> , <b>2019</b> , 104, e474-e477	6.6	0
37	Dalteparin for pregnant women with thrombophilia - authors' reply. <i>Lancet, The</i> , <b>2015</b> , 385, 690	4.0	0
36	Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , <b>2021</b> , 208, 79-82	8.2	0
35	Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care. <i>Journal of Health Economics and Outcomes Research</i> , <b>2019</b> , 6, 160-173	1.6	0
34	Outcomes of Pulmonary Embolism In Surgical Patients: A Retrospective Cohort Study. <i>Blood</i> , <b>2010</b> , 116, 3180-3180	2.2	0
33	Extended therapy for unprovoked venous thromboembolism: when is it indicated?. <i>Blood Advances</i> , <b>2019</b> , 3, 499	7.8	0
32	Evaluation of definitions for oral anticoagulant-associated major bleeding: A population-based cohort study.. <i>Thrombosis Research</i> , <b>2022</b> , 213, 57-64	8.2	0
31	Inferior Vena Cava Filters in the Management of Venous Thromboembolism-Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 321, 1007	27.4	
30	Uitsluiten van DVT met een klinische beslisregel. <i>Huisarts En Wetenschap</i> , <b>2014</b> , 57, 626-628	0.1	
29	Therapies for venous thromboembolism--reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 2543-4	27.4	

28	Diagnostic Management Strategies in Patients with Suspected Deep Vein Thrombosis	315-327	
27	Apixaban Anti-Xa Level Monitoring in Treatment of Provoked Acute Upper Extremity Deep Vein Thrombosis for Patient on Dialysis: A Case Report. <i>Blood</i> , <b>2020</b> , 136, 14-14		2.2
26	Efficacy and Safety of Primary Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients with Cancer and Central Venous Catheter: A Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2021</b> , 138, 2139-2139		2.2
25	Factor XIII Val34Leu Polymorphism Is Protective Against Venous Thromboembolism; a Meta-Analysis.. <i>Blood</i> , <b>2004</b> , 104, 3512-3512		2.2
24	Factor XIII Val34Leu Polymorphism and the Risk of Myocardial Infarction: A Meta-Analysis.. <i>Blood</i> , <b>2005</b> , 106, 1637-1637		2.2
23	The Effect of Dalteparin on Coagulation Activation during Pregnancy in Women with Thrombophilia: A Randomised Trial.. <i>Blood</i> , <b>2006</b> , 108, 874-874		2.2
22	Cost-Utility Analysis of Apixaban Compared to Usual Care for the Primary Thromboprophylaxis of Ambulatory Cancer Patients Initiating Chemotherapy. <i>Blood</i> , <b>2019</b> , 134, 329-329		2.2
21	Brain Natriuretic Peptide, Troponin and D-Dimer Levels in Relation to Long-Term Functional Outcome after a First Episode of Pulmonary Embolism: Results from the E.L.O.P.E. Study. <i>Blood</i> , <b>2015</b> , 126, 649-649		2.2
20	Do Genetic Contributors to Warfarin Responsiveness or Common Thrombophilias Influence the Risk of Major Bleeding in Patients on Extended Duration Vitamin K Antagonist (VKA) for Venous Thromboembolic Disease?. <i>Blood</i> , <b>2016</b> , 128, 272-272		2.2
19	External Validation of a Clinical and Claims-Based Approach for Predicting 90-Day Post-Pulmonary Embolism Outcomes Among US Veterans. <i>Blood</i> , <b>2016</b> , 128, 533-533		2.2
18	Reduced Costs and Length-of-Stay Associated with Rivaroxaban As Compared to Parenteral Bridging and Warfarin in Pulmonary Embolism Patients Managed in Observation Status. <i>Blood</i> , <b>2016</b> , 128, 2337-2337		2.2
17	Risk of Venous Thromboembolism Recurrence Among Rivaroxaban Treated Patients Who Continued Versus Discontinued Therapy: Analyses Among VTE Patients. <i>Blood</i> , <b>2016</b> , 128, 144-144		2.2
16	Cost-Effectiveness of Rivaroxaban as VTE Prophylaxis after Total Hip Replacement in Canada.. <i>Blood</i> , <b>2008</b> , 112, 1291-1291		2.2
15	Practical Application of the 10 Mg Warfarin Initiation Nomogram. <i>Blood</i> , <b>2008</b> , 112, 4054-4054		2.2
14	VIDAS D-Dimer in Combination with Clinical Pre-Test Probability to Rule out Pulmonary Embolism. A Systematic Review of the Management Outcome Studies.. <i>Blood</i> , <b>2008</b> , 112, 1811-1811		2.2
13	Dose Escalation of Low Molecular Weight Heparin to Manage VTE Treatment Failure in Cancer Patients. <i>Blood</i> , <b>2008</b> , 112, 4050-4050		2.2
12	Outcome of Saddle Pulmonary Embolism: A Nested Case-Control Study.. <i>Blood</i> , <b>2010</b> , 116, 1102-1102		2.2
11	Validation of A Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism In Patients with Cancer-Associated Venous Thromboembolism. <i>Blood</i> , <b>2010</b> , 116, 4209-4209		2.2

- 10 Patients with Cancer Who Develop a First Venous Thromboembolic Event After Surgery Are at High Risk of Venous Thromboembolism Recurrence During the Anticoagulation Period. *Blood*, **2010**, 116, 4202-4202 2.2
- 9 Safety of Outpatient Treatment In Acute Pulmonary Embolism.. *Blood*, **2010**, 116, 3796-3796 2.2
- 8 Comparison of the Villalta Post Thrombotic Syndrome (PTS) Score in the Ipsilateral Versus Contralateral Leg After a First Unprovoked Deep Vein Thrombosis (DVT): Results From the REVERSE Study. *Blood*, **2011**, 118, 1236-1236 2.2
- 7 Frequency and Predictors of Post-Thrombotic Syndrome in Patients with a First, Unprovoked Deep Vein Thrombosis and No Prior Primary Venous Insufficiency: Results From the REVERSE Cohort Study,. *Blood*, **2011**, 118, 3332-3332 2.2
- 6 Performance Of The Simplified Pesi Score In Patients With Pulmonary Embolism Treated With Rivaroxaban Or Standard Therapy. *Blood*, **2013**, 122, 1139-1139 2.2
- 5 The Effectiveness Of 30-40 Mm Hg Compression Stockings To Treat Acute Leg Pain Associated With Proximal Deep Vein Thrombosis: Results From The Sox Randomized Controlled Trial. *Blood*, **2013**, 122, 1126-1126 2.2
- 4 Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer. *Thrombosis Research*, **2020**, 196, 437-443 8.2
- 3 Direct oral anticoagulant use in special populations. *Current Opinion in Pulmonary Medicine*, **2021**, 27, 311-318 3
- 2 Media portrayals of pulmonary embolism. *Thrombosis Research*, **2021**, 206, 52-54 8.2
- 1 Deep Vein Thrombosis 113-122